blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2210888

EP2210888 - Stable micronized candesartan cilexetil and methods for preparing thereof [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.02.2014
Database last updated on 07.10.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
5 Basel Street, P.O. Box 3190
49131 Petah Tiqva / IL
[2013/17]
Former [2010/30]For all designated states
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
5 Basel Street, P.O. Box 3190
49131 Petah Tiqva / IL
Inventor(s)01 / Kurgan, Ziv
28/7 Itzhak Shatal Street
Beer-sheva / IL
02 / Pesachovich, Michael
5/11 Zvulun Hammer Str
Givat-shmuel / IL
 [2013/17]
Former [2010/30]01 / Kurgan, Ziv
28/7 Itzhak Shatal Street
Beer-sheva / IL
02 / Pesachovich, Michael
5/11 Zvulun Hammer Str
Givat-shmuel / IL
Representative(s)Gallagher, Kirk James, et al
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
[N/P]
Former [2012/11]Gallagher, Kirk James, et al
D Young & Co LLP 120 Holborn
London EC1N 2DY / GB
Former [2010/30]Lumsden, Stuart Edward Henry
D Young & Co LLP 120 Holborn
London EC1N 2DY / GB
Application number, filing date10156812.910.05.2006
[2010/30]
Priority number, dateUS20050679952P10.05.2005         Original published format: US 679952 P
US20050680115P11.05.2005         Original published format: US 680115 P
US20050684455P24.05.2005         Original published format: US 684455 P
US20050707417P10.08.2005         Original published format: US 707417 P
US20050709954P19.08.2005         Original published format: US 709954 P
US20050716995P13.09.2005         Original published format: US 716995 P
US20050722388P29.09.2005         Original published format: US 722388 P
[2010/30]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2210888
Date:28.07.2010
Language:EN
[2010/30]
Type: A3 Search report 
No.:EP2210888
Date:15.09.2010
[2010/37]
Type: B1 Patent specification 
No.:EP2210888
Date:24.04.2013
Language:EN
[2013/17]
Search report(s)(Supplementary) European search report - dispatched on:EP13.08.2010
ClassificationIPC:C07D403/10, A61K31/4184, A61P9/10
[2010/30]
CPC:
C07D403/10 (EP,KR,US); A61K31/4184 (EP,KR,US); A61K9/141 (EP,US);
A61P13/12 (EP); A61P9/00 (EP); A61P9/04 (EP);
A61P9/10 (EP); A61P9/12 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/30]
TitleGerman:Stabiles mikronisiertes Candesartan-Cilexetil und Herstellungsverfahren[2010/30]
English:Stable micronized candesartan cilexetil and methods for preparing thereof[2010/30]
French:Candesartan cilexetil micronisé stable et son procédé de préparation[2010/30]
Examination procedure26.03.2010Examination requested  [2010/30]
01.09.2010Despatch of a communication from the examining division (Time limit: M04)
10.01.2011Reply to a communication from the examining division
27.06.2011Despatch of a communication from the examining division (Time limit: M04)
07.11.2011Reply to a communication from the examining division
19.01.2012Observations by third parties
28.01.2013Date of oral proceedings
15.02.2013Minutes of oral proceedings despatched
22.02.2013Communication of intention to grant the patent
12.03.2013Fee for grant paid
12.03.2013Fee for publishing/printing paid
Parent application(s)   TooltipEP06759583.5  / EP1763525
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060759583) is  04.05.2007
Opposition(s)27.01.2014No opposition filed within time limit [2014/14]
Fees paidRenewal fee
26.03.2010Renewal fee patent year 03
26.03.2010Renewal fee patent year 04
28.05.2010Renewal fee patent year 05
24.05.2011Renewal fee patent year 06
22.05.2012Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.05.2006
AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
LV24.04.2013
MC24.04.2013
NL24.04.2013
PL24.04.2013
RO24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
IE10.05.2013
LU10.05.2013
CH31.05.2013
LI31.05.2013
BG24.07.2013
GB24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
[2015/34]
Former [2014/21]AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
LV24.04.2013
MC24.04.2013
NL24.04.2013
PL24.04.2013
RO24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
IE10.05.2013
CH31.05.2013
LI31.05.2013
BG24.07.2013
GB24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2014/20]AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
LV24.04.2013
MC24.04.2013
NL24.04.2013
PL24.04.2013
RO24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
IE10.05.2013
CH31.05.2013
LI31.05.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2014/14]AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
LV24.04.2013
MC24.04.2013
NL24.04.2013
PL24.04.2013
RO24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
CH31.05.2013
LI31.05.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2014/11]AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
LV24.04.2013
MC24.04.2013
PL24.04.2013
RO24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
CH31.05.2013
LI31.05.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2014/10]AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
LV24.04.2013
MC24.04.2013
PL24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
CH31.05.2013
LI31.05.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2014/09]AT24.04.2013
BE24.04.2013
CY24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
LV24.04.2013
MC24.04.2013
PL24.04.2013
SE24.04.2013
SI24.04.2013
CH31.05.2013
LI31.05.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2014/08]AT24.04.2013
BE24.04.2013
CY24.04.2013
FI24.04.2013
LT24.04.2013
LV24.04.2013
MC24.04.2013
PL24.04.2013
SE24.04.2013
SI24.04.2013
CH31.05.2013
LI31.05.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2013/52]AT24.04.2013
BE24.04.2013
CY24.04.2013
FI24.04.2013
LT24.04.2013
LV24.04.2013
PL24.04.2013
SE24.04.2013
SI24.04.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2013/50]AT24.04.2013
BE24.04.2013
FI24.04.2013
LT24.04.2013
LV24.04.2013
PL24.04.2013
SE24.04.2013
SI24.04.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2013/49]AT24.04.2013
BE24.04.2013
FI24.04.2013
LT24.04.2013
SE24.04.2013
SI24.04.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2013/48]AT24.04.2013
LT24.04.2013
IS24.08.2013
PT26.08.2013
Former [2013/47]LT24.04.2013
PT26.08.2013
Documents cited:Search[XD]US5196444  (NAKA TAKEHIKO [US], et al) [XD] 1-14 * Abstract; claims; working example 7; experimental example 1; figure 3. *;
 [A]WO0067892  (ASTRAZENECA AB [SE], et al) [A] 1-14 * Abstract; claims 1, 21; page 11, lines 23-31 and figures 11b, 12b. *;
 [XP]WO2005111021  (TEVA PHARMA [IL], et al) [XP] 1-14 * Abstract; claims; examples 1 and 2. *;
 [E]WO2006122254  (TEVA PHARMA [IL], et al) [E] 1-14 * the whole document *;
 [E]EP1763525  (TEVA PHARMA [IL]) [E] 1-14 * the whole document *;
 [XD]  - MATSUNAGA ET AL., "Solid-state characterization of candesartan cilexetil (TCV-116): crystal structure and molecular mobility", CHEM. PHARM. BULL., (199902), vol. 47, no. 2, ISSN 0009-2363, pages 182 - 186, XP002957606 [XD] 1-5 * Pages 182-183, section "Preparation of Polymorphs and Amorphous Form"; page 183, chart 2 and section "Thermal Analysis"; page 184, figure 2 and table 2. *
 [X]  - Rote Liste Service GmbH (editor), Rote Liste 2004, Aulendorf, Editio Cantor Verlag, (2004), XP002594024 [X] 1-5,12-14 * Entries 17154 (Atacand Tabletten) and 17155 (Blopross Tabletten). *
 [A]  - BLACK ET AL., "Laser-based techniques for particle-size measurement: a review of sizing methods and their industrial applications", PROGRESS IN ENERGY AND COMBUSTION SCIENCE, (1996), vol. 22, no. 3, ISSN 0360-1285, pages 267 - 306, XP004068954 [A] 1-14 * Chapters 2.1, 2.2, 3. *

DOI:   http://dx.doi.org/10.1016/S0360-1285(96)00008-1
 [A]  - Malvern Instruments, MAN 0101 Issue 1.3 - Getting Started Manual for Mastersizer X and Mastersizer S., Malvern (UK), Malvern Instruments Ltd., (199708), XP002594025 [A] 1-14 * the whole document *
Examination   - Malvern Instruments: "Mastersizer S, User Manual MAN 0096 Issue 1.0", November 1994, Malvern Instruments Ltd., Malvern (UK), chapter 2, pages 11-13, chapter 8, pages 87-90.
    - Zeng, "Particulate Analysis - Particle Size", Zeng, Storey, Ymen (eds.), Solid State Characterization of Pharmaceuticals, Chichester, John Wiley & Sons, (20110531), pages 388 - 425, Chapter 11, ISBN 9781405134941
    - Rawle: Technical Paper - Basic Principles of Particle Size Analysis, Malvern Intruments, pages 1-8.
    - US Pharmacopoeia, vol 23 (1995), chapter 941: x-ray diffraction, pages 1843-1844.
    - Connolly: Introduction to X-ray Powder Diffraction, 2007, pages 1-9. Accessible from the internet under: http://epswww.unm.edu/xrd/xrdclass/01-XRD-Intro.pdf
by applicantUS5196444
    - CHEM. PHARM. BULL., (1999), vol. 47, no. 2, pages 182 - 186
other   - THIBERT R. ET AL, "Micronization of Pharmaceutical Solids", MML SERIES, (1999), vol. 1, pages 327 - 347, XP003028691
    - "ARL X'TRA diffraktometer (Press release attached)", LABO ONLINE, pages 1 - 6, XP003028692
    - V. ALEXEEV, Analise Quantitativa, 3rd Ed. (English translation enclosed), LIVRARIA LOPES DA SILVA, (1983), pages 97 - 98, XP003028693
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.